Naslov
Efficacy of the PROBITECT-A emollient plus during a 4-week follow-up in subjects with mild atopic dermatitis

Autori
Perić, Mihaela ; Hrestak, Dora ; Čipčić Paljetak, Hana ; Matijašić, Mario ; Ljubojević Hadžavdić, Suzana ; Duvančić, Tomislav ; Kuna, Matea ; Filipović, Nika ; Lugović Mihić, Liborija ; Prtajin, Marta ; Prkačin, Ivana ; Mikulecky, Mirta ; Meglaj, Mladen ; Ledić Drvar, Daniela

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Skup
2nd Symposium of the International Contact Dermatitis Research Group (ICDRG) in cooperation with Croatian Dermatovenereological Society of the Croatian Medical Association

Mjesto i datum
Split, Hrvatska, 31.03.2023. - 02.04.2023

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
emollient plus, atopic dermatitis, clinical study

Sažetak
PROBITECT-A is a new emollient plus lotion consisting of a cosmetic base (water-in-oil inverse emulsion with a high proportion of lipids) with three active ingredients based on microbiota (ectoin and a combination of inactivated Lactobacillus and Bifidobacterium bacterial strains preparations) designed for alleviating symptoms of atopic dermatitis (AD). The goal of the clinical study was to assess the safety and efficacy of PROBITECT-A during 4 weeks in adult AD patients. The study was designed as a comparison of two therapies, PROBITECT-A and control treatment (formulation without active ingredients), on adult patients with diagnosed mild atopic dermatitis. Both treatments were applied twice daily, each on one side of the body (left/right on the same patient) during 4 weeks. Efficacy was assessed by determining changes between groups and 3 time- points (day 0, week 2 and 4). Parameters measured were: modified objective SCORAD index, transepidermal water loss, hydration, erythema (mexameter), redness (3D camera), lichenification, elasticity, pH, scaliness and skin microtexture. Out of 84 recruited patients, 32 completed the study according to protocol. PROBITECT-A significantly decreased redness and lichenification compared to control emollient on week 2, but not on week 4. Efficacy of both products to relieve the signs and symptoms of the disease during observation period was demonstrated. Specifically, PROBITECT-A significantly decreased erythema and maximal redness, while both treatments significantly decreased SCORAD, as well as skin redness (total and average) and increased hydration and elasticity. PROBITECT-A, a new emollient plus based on microbiota, is more effective in decreasing redness and lichenification than the control emollient, however, both emollients significantly decreased SCORAD, as well as skin redness (total, average) and increased hydration and elasticity of the AD skin.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA